Cormedix Inc (NYSEAMERICAN:CRMD) Has Decline in Shorts


Investors sentiment decreased to 0.78 in Q2 2018. Its down 0.04, from 0.82 in 2018Q1. It worsened, as 4 investors sold CorMedix, Inc. shares while 5 reduced holdings. 4 funds opened positions while 3 raised stakes. 3.29 million shares or 8.35% less from 3.59 million shares in 2018Q1 were reported.
Morgan Stanley accumulated 14,555 shares. Hightower Advisors Ltd Limited Liability Company holds 47,188 shares or 0% of its portfolio. Arizona-based Tci Wealth Advsr has invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). State Street Corporation, a Massachusetts-based fund reported 17,767 shares. Bnp Paribas Arbitrage accumulated 23 shares or 0% of the stock. Grp Inc One Trading Limited Partnership owns 0% invested in CorMedix, Inc. (NYSEAMERICAN:CRMD) for 44,648 shares. Franklin Resource Incorporated holds 0% or 223,254 shares in its portfolio. Citadel Advsrs Limited Liability invested in 41,661 shares or 0% of the stock. Moreover, Virtu Finance Limited Liability Corp has 0% invested in CorMedix, Inc. (NYSEAMERICAN:CRMD). Financial Bank Of Ny Mellon stated it has 37,660 shares or 0% of all its holdings. Cetera Advsr Limited Liability Company reported 10,000 shares. Geode Management stated it has 295,008 shares or 0% of all its holdings. Sei Company reported 0% stake. Taurus Asset Mngmt Ltd Liability stated it has 30,000 shares. Private Advisor Group Incorporated Ltd Company reported 12,240 shares.

Since November 23, 2018, it had 4 insider buys, and 0 insider sales for $487,653 activity. Baluch Khoso bought 25,000 shares worth $30,495. $64,795 worth of CorMedix, Inc. (NYSEAMERICAN:CRMD) shares were bought by Kaplan Myron. Cook Robert W. had bought 25,000 shares worth $29,213.

The stock of Cormedix Inc (NYSEAMERICAN:CRMD) registered a decrease of 6.82% in short interest. CRMD’s total short interest was 8.08M shares in December as published by FINRA. Its down 6.82% from 8.67M shares, reported previously. With 3.43 million shares average volume, it will take short sellers 2 days to cover their CRMD’s short positions.

The stock increased 22.22% or $0.3 during the last trading session, reaching $1.65. About 8.15M shares traded or 110.29% up from the average. CorMedix, Inc. (NYSEAMERICAN:CRMD) has risen 38.78% since December 7, 2017 and is uptrending. It has outperformed by 23.16% the S&P500.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $165.94 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

More notable recent CorMedix, Inc. (NYSEAMERICAN:CRMD) news were published by: which released: “CorMedix Inc. to Present at The 20th Annual Rodman & Renshaw Global Investment Conference – Press Release – Digital Journal” on August 30, 2018, also with their article: “CorMedix Exec VP of Tech Operations Armstrong Buys 250,000 @ Avg Price: $1.45 – Stockhouse” published on November 30, 2018, published: “CorMedix’s (CRMD) CEO Khoso Baluch on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” on May 15, 2018. More interesting news about CorMedix, Inc. (NYSEAMERICAN:CRMD) were released by: and their article: “Cormedix Inc. Reports Third Quarter Financial Results and Provides Business Update – Press Release – Digital Journal” published on November 14, 2018 as well as‘s news article titled: “CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance – Press Release – Digital Journal” with publication date: August 31, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.